Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SimS-1: Simvastatin Added to Adjuvant S-1 After Curative Resection for Pancreatic Cancer
jRCTs051260114Phase 2Recruiting
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of simvastatin in pancreatic adenocarcinoma (PDAC). Primary endpoint: Recurrence-free survival. Started Jul 2026; status: recruiting.
02
Drugs
simvastatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCTs051260114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051260114.